- Home
- Companies
- Newcells Biotech Limited
- Products
- Human Lung Fibroblasts
Human Lung Fibroblasts
Human lung fibroblast model to test the efficacy of anti-fibrotic agents in vitro. Newcells human primary lung fibroblast model is the basis of our FMT assay to evaluate anti-fibrotic therapies in vitro at high throughput. The assay replicates extracellular matrix deposition (ECM) observed in vivo when lung fibroblast injury leads to activation and proliferation. Following injury, pulmonary fibroblasts proliferate playing an important role in the repair and remodelling of tissue. However, excessive proliferation of fibroblasts can result in abnormal tissue function.
- The readouts are determined by high-content imaging (HCI) and image analysis
- Cell number by nuclei staining
- Proliferation rates by EdU incorporation
- Deposition of Collagen I and Collagen III by immunocytochemistry
- Detection of α-SMA
Accelerate your lead compound selection by understanding their mode of action in a model of lung fibrosis
- Evaluate therapeutic candidates targeting idiopathic pulmonary fibrosis (IPF)
- Easily and accurately model lung fibrosis in vitro
- High throughput to accelerate drug discovery
Fibroblast-to-Myofibroblast Transition (FMT) assay
Newcells has developed a robust and well validated model of FMT from primary lung fibroblasts isolated from healthy and IPF donors. Through stimulation of the well-established fibrogenic mediator TGF-ß, lung fibroblasts are activated and differentiate into myofibroblasts producing increased levels of extracellular matrix (Collagen I and III), which can be quantified. With this model, the ability of small molecules to reduce or increase ECM deposition can be assessed at high throughput.
- Low passage normal human primary fibroblasts isolated from adult lung tissue
- Available from multiple donors including both healthy and IPF (idiopathic pulmonary fibrosis) donors